5-·úÄòà×शÔÌåÍâÅàÑøñ£ºÛ¸í´ñ³ÉÏËάϸ°ûµÄÒÖÖÆ¼°°ëÊýÒÖ֯ō¶È*¡ï
×ó×Ú±¦£¬ÀîС¾²£¬Äþ½ðÁú£¬¹¨éóÒ»£¬ÅË×£±ó£¬ÖÜ è¤
¿ÎÌâ±³¾°£º¿ÎÌâΪ°²»ÕÊ¡½ÌÓýÌü×ÔÈ»¿ÆÑ§»ù½ð×ÊÖúÏîÄ¿(070413102)¡£5-·úÄòà×à¤ÊÇ´«Í³¿¹´úлҩÎÆäÓÕµ¼¶àÖÖÖ×Áöϸ°ûµÄµòÍöÒѵõ½³ä·ÖÂÛÖ¤£¬½üÀ´¹úÄÚÍâ¾ùÓÐ5-·úÄòà×à¤Ó¦ÓÃÓÚ²¡ÀíÐÔñ£ºÛÖÎÁƵÄÁÙ´²±¨µÀ£¬µ«ÆäÒ©Îï×÷ÓûúÖÆÉÐÎÞÈ·ÇÐÈ϶¨¡£±¾ÊµÑéÀûÓÃÌåÍâϸ°ûÅàÑø¼¼Êõ£¬Ì½Ë÷5-·úÄòà×शÔñ£ºÛ¸í´ñ³ÉÏËάϸ°ûÔöÖ³ºÍµòÍöµÄÉúÎïѧӰÏì¡£
Ó¦ÓÃÒªµã£ºÊµÑé֤ʵµÍŨ¶È5-·úÄòà×शÔÌåÍâÅàÑøñ£ºÛ¸í´ñ³ÉÏËάϸ°ûÓÐÒÖÖÆÔöÖ³ºÍÓÕµ¼µòÍö×÷Óá£ÔÚÒ©Îïϸ°û¶¾ÐÔ½ÏÈõµÄŨ¶È·¶Î§Ï£¬ËæÒ©ÎïŨ¶ÈµÄÔö¼Ó£¬Ï¸°ûµòÍöÂÊËæÖ®Éý¸ß¡£²ÉÓõÍŨ¶È¡¢¶ÌÖÜÆÚ×¢Éä5-·úÄòà×िÉÄÜÊÇÖÎÁÆñ£ºÛ¸í´ñ½ÏΪ°²È«¡¢ÓÐЧµÄ·½·¨¡£
ͬÐÐÆÀ¼Û£ºÎÄÕ¹۲ì5-·úÄòà×शÔÌåÍâñ£ºÛ¸í´ñ³ÉÏËάϸ°ûµÄÉúÎïѧӰÏìÊǶÔ5-·úÄòà×à¤ÖÎÁÆñ£ºÛ¸í´ñ»úÖÆµÄÓÐÒæÌ½ÌÖ£¬ÌرðÊÇ̽ÌÖÁË5-·úÄòà×शÔñ£ºÛ¸í´ñ³ÉÏËάϸ°ûµÄ°ëÊýÒÖ֯ō¶È£¬¶ÔÓÚÖ¸µ¼ÁÙ´²Ó¦ÓþßÓÐÖØÒª¼ÛÖµ¡£ÿÿ
1»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ¸½ÊôкÍÒ½ÔºÐÄÄÚ¿Æ£¬ºþ±±Ê¡Î人ÊÐ 430022£»2ôßÄÏ´óѧµÚ¶þÁÙ´²Ò½Ñ§Ôº£¨ÉîÛÚÊÐÈËÃñÒ½Ôº£©ÐÄÄÚ¿Æ£¬¹ã¶«Ê¡ÉîÛÚÊÐ
518020
°²»ÕÒ½¿Æ´óѧµÚÒ»¸½ÊôÒ½ÔºÕûÐÎÍâ¿Æ£¬°²»ÕÊ¡ºÏ·ÊÊÐ 230032
×ó×Ú±¦¡ï£¬ÄУ¬1981ÄêÉú£¬°²»ÕÊ¡°²ÇìÊÐÈË£¬ºº×壬°²»ÕÒ½¿Æ´óѧÔÚ¶Á˶ʿ£¬×¡ÔºÒ½Ê¦£¬Ö÷Òª´ÓÊÂñ£ºÛ»ù´¡·½ÃæµÄÑо¿¡£
ayzuozongbao@
yahoo.com.cn
ͨѶ×÷ÕߣºÀîС¾²£¬½ÌÊÚ£¬Ë¶Ê¿Éúµ¼Ê¦£¬°²»ÕÒ½¿Æ´óѧµÚÒ»¸½ÊôÒ½ÔºÕûÐÎÍâ¿Æ£¬°²»ÕÊ¡ºÏ·ÊÊÐ 230032
lixiaojing5@163.com
°²»ÕÊ¡½ÌÓýÌü×ÔÈ»¿ÆÑ§»ù½ð×ÊÖúÏîÄ¿(0704131 02)*
ÕªÒª
Ä¿µÄ:¹úÄÚÍâһЩѧÕßʹÓô«Í³¿¹´úлҩÎï5-·úÄòà×षÀÖ¹ÏËά»¯£¬ÔÚÖÎÁÆñ£ºÛ¸í´ñ·½ÃæÈ¡µÃÁËÒ»¶¨µÄÁÙ´²ÁÆÐ§£¬µ«¶ÔÆäÒ©Îï×÷ÓûúÖÆÒÔ¼°ÁÙ´²Ò©ÎïÓ¦ÓõÄŨ¶ÈÉÐÎÞÈ·ÇÐÈ϶¨¡£ÊµÑéÄâ½øÒ»²½ÑéÖ¤5-·úÄòà×शÔÌåÍâÅàÑøñ£ºÛ¸í´ñ³ÉÏËάϸ°ûÔöÖ³µÄÒÖÖÆÒÔ¼°°ëÊýÒÖ֯ō¶È¡£
·½·¨£ºÊµÑéÓÚ2006-09/2007-07ÔÚ°²»ÕÒ½¿Æ´óѧ΢ÉúÎï½ÌÑÐÊÒ¼°°²»ÕÒ½¿Æ´óѧ¸½ÊôÒ½ÔºÖÐÐÄʵÑéÊÒÍê³É¡£¢ÙʵÑé²ÄÁÏ£º6Àýñ£ºÛ¸í´ñ£¨¶ú´¹¡¢´óÍȸ÷1Àý¡¢ÐØÇ°¡¢Éϱ۸÷2Àý£©¾ùΪ°²»ÕÒ½¿Æ´óѧ¸½ÊôÒ½ÔºÕûÐÎÍâ¿ÆÊÖÊõ²¡Àý£¬¾ùÎÞϵͳÐÔ¼²²¡ºÍ¼¤ËØ¡¢ÆäËûÒ©Îï×¢ÉäÊ·£¬¶ÔÓÃÓÚʵÑéµÄËùÈ¡×éÖ¯»¼Õß¾ùÖªÇéͬÒâ¡£ÖÎÁÆ·½°¸¾Ò½ÔºÒ½Ñ§Â×ÀíίԱ»áÅú×¼¡£¢ÚʵÑé·½·¨£º³ÉÏËάϸ°ûÌåÍâÔ´úÅàÑø£¬´ýϸ°ûÈںϺ󴫴ú£¬ÊµÑéËùÓÃϸ°û¾ùΪ´¦ÓÚ4~8´ú¶ÔÊýÉú³¤ÆÚµÄ³ÉÏËάϸ°û¡£½«²»Í¬Å¨¶È5-·úÄòà×à¤(0.1£¬0.2£¬0.4£¬0.8£¬1.6 g/L)·Ö±ð¶Ô4~8´úñ£ºÛ¸í´ñ³ÉÏËάϸ°û½øÐиÉÔ¤72 h¡£ÔÙÑ¡ÓýӽüIC50µÄ5¸öŨ¶È£º0.2£¬0.3£¬0.4£¬0.5£¬0.6 g/L£¬×÷ΪÓàÏÂʵÑéŨ¶È¡£¢ÛʵÑéÆÀ¹À£º²ÉÓÃËļ׻ùżµªßòÑαÈÉ«·¨¼ì²â¸÷Ũ¶ÈÒ©Îï¶Ô³ÉÏËάϸ°ûµÄÒÖÖÆÂÊ£¬¼ÆËã5-·úÄòà×शÔñ£ºÛ¸í´ñ³ÉÏËάϸ°ûµÄ°ëÊýÒÖ֯ō¶È£¨IC50£©Öµ¡£Ó¦ÓÃÁ÷ʽϸ°ûÊõ·ÖÎö·¨¹Û²ì5-·úÄòà×सÉÔ¤ºóñ£ºÛ¸í´ñ³ÉÏËάϸ°ûµÄϸ°ûÖÜÆÚ±ä»¯¼°Ï¸°ûµòÍö°Ù·ÖÂÊ£»Ó¦ÓÃHoechst 33258Ó«¹âȾɫ·¨¹Û²ìµòÍö³ÉÏËάϸ°ûµÄÐÎÌ¬Ñ§ÌØÕ÷¡£
½á¹û£º6Àýñ£ºÛ¸í´ñ±ê±¾Ô´úÅàÑø³ÉÏËάϸ°û³É»îÁ¼ºÃ£¬¾ùÓÃÓÚʵÑ飬½øÈë½á¹û·ÖÎö¡£¢Ù0.1£¬0.2£¬0.4£¬0.8£¬1.6 g/L 5-·úÄòà×सÉÔ¤72 h ºó£¬Ï¸°ûÒÖÖÆÂÊ×é¼äÁ½Á½±È½Ï²îÒì¾ùÓÐÏÔÖøÐÔ£¨P < 0.01£©¡£×÷ͼµÃ°ëÊýÒÖ֯ō¶ÈIC50Ϊ£¨0.400¡À0.032£©g/L¡£¢Ú0.2£¬0.3£¬0.4£¬0.5£¬0.6 g/L 5-·úÄòà×सÉÔ¤48 h ºó£¬Ï¸°ûµòÍöÂÊ×é¼äÁ½Á½±È½Ï²îÒìÏÔÖø£¨P < 0.05£©£¬Óë¶ÔÕÕ×é±È½Ï£¬²îÒìÓÐÏÔÖøÐÔÒâÒå(P < 0.01)£»ÊµÑé×éÓë¶ÔÕÕ×éϸ°ûÖÜÆÚ°Ù·ÖÊý±È½Ï£¬±íÏÖΪG0/G1ÆÚÍ£ÖÍ£¬SÆÚ¼õÉÙ£¬¸÷×é¼äÁ½Á½±È½Ï²îÒìÓÐÏÔÖøÐÔÒâÒ壨P < 0.05£©¡£¢Û¸÷Ũ¶È5-·úÄòà×सÉÔ¤48 h ºó£¬Hoechst 33258Ó«¹âȾɫ¹Û²ì³ÉÏËάϸ°û¾ù·¢Éú²»Í¬³Ì¶ÈµòÍö¡£
½áÂÛ£º5-·úÄòà×शÔñ£ºÛ¸í´ñ³ÉÏËάϸ°û¾ßÓÐÒÖÖÆÔöÖ³ºÍÓÕµ¼µòÍöµÄ×÷ÓᣵÍŨ¶È¡¢¶ÌÖÜÆÚ×¢Éä5-·úÄòà×िÉÄÜÊÇÖÎÁÆñ£ºÛ¸í´ñµÄÒ»ÖÖÐÂ˼·¡£
¹Ø¼ü´Ê£ºñ£ºÛ¸í´ñ£»·úÄòà×ण»³ÉÏËάϸ°û£»Ï¸°ûÔöÖ³£»Ï¸°ûµòÍö£»×éÖ¯¹¹½¨
×ó×Ú±¦£¬ÀîС¾²£¬Äþ½ðÁú£¬¹¨éóÒ»£¬ÅË×£±ó£¬ÖÜ褣®5-·úÄòà×शÔÌåÍâÅàÑøñ£ºÛ¸í´ñ³ÉÏËάϸ°ûµÄÒÖÖÆ¼°°ëÊýÒÖ֯ō¶È[J].Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´£¬2008£¬12(7):1235-1238 [www.zglckf.com/zglckf/ejournal/upfiles/08-7/7k-1235(ps).pdf]
ÖÐͼ·ÖÀàºÅ:R318
ÎÄÏ×±êʶÂë:A
ÎÄÕ±àºÅ:1673-8225
(2008)07-01235-04
ÊÕ¸åÈÕÆÚ£º2007-11-01
ÐÞ»ØÈÕÆÚ£º2007-12-28
(07-50-11-5964/WL¡¤A£©
Inhibitory effect of 5-fluorouracil on in vitro cultured human keloid fibroblasts and determination of 50% inhibitory concentration of 5-fluorouracil
Abstract
AIM:5- fluorouracil is always used to prevent fibrosis, which has achieved certain curative effect on keloid in clinic. However, its mechanism and application dosage in clinic are still uncertain. This study explored the inhibitory effects and concentration of 5-fluorouracil on the proliferation of human keloid fibroblasts in vitro.
METHODS: The experiment was performed at Microbes Department of Anhui Medical University and the center laboratory of Affiliated Hospital of Anhui Medical University from September 2006 to July 2007. ¢ÙKeloids of ear lobe, thigh, chest and upper arm were derived from 6 cases of Department of Plastic Surgery, First Affiliated Hospital of Anhui Medical University. All the patients did not have any systemic disease or drug injection like hormone. The informed consent was obtained from the patients, and the experiment was admitted by the Hospital Ethics Committee. ¢ÚFibroblasts were cultured in vitro, and the ¢ô-¢ø generation cells at exponential phase of growth were used for experiment. Keloid fibroblasts were stimulated with 5-fluorouracil (0.1, 0.2, 0.4, 0.8, and 1.6 g/L) for 72 hours. In addition, 0.2, 0.3, 0.4, 0.5 and 0.6 g/L 5-fluorouracil were prepared for the following experiment. ¢ÛThe inhibition ratio and 50% inhibitory concentration (IC50) were calculated by MTT. The cell apoptosis and cell cycle were measured by flow cytometry. The cell morphological character was observed by Hoechst 33258 fluorescent staining.
RESULTS: Six keloid specimens were primarily cultured well, and all were included in the final analysis. ¢ÙAfter 5-fluorouracil (0.1, 0.2, 0.4, 0.8, and 1.6 g/L) intervention for 72 hours, the inhibition ratio were significantly different between every two groups (P < 0.01). The IC50 was (0.400¡À0.032) g/L by mapping. ¢ÚAfter 5-fluorouracil (0.2, 0.3, 0.4, 0.5, and 0.6 g/L) intervention for 48 hours, the apoptosis rate had significant differences between every two groups (P < 0.05). Compared with the control group cells, the differences were statistically significant (P < 0.01). Compared with the control group cells, the number of experiment cells at phase G0/G1 significantly increased and S decreased (P < 0.05). ¢ÛBy Hoechst 33258 fluorescent staining, the keloid fibroblasts interfered with 5-fluorouracil showed apoptosis at different extents.
CONCLUSION: 5-fluorouracil can inhibit proliferation and induce apoptosis of human keloid fibroblasts in vitro. Low concentration and short-period injection with 5-fluorouracil would be a new ideal for keloid treatment.
Zuo ZB, Li XJ, Ning JL, Gong YY, Pan ZB, Zhou Y. Inhibitory effect of 5-fluorouracil on in vitro cultured human keloid fibroblasts and determination of 50% inhibitory concentration of 5-fluorouracil .Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2008;12(7):1235-1238(China) [www.zglckf.com/zglckf/ejournal/upfiles/08-7/7k-1235(ps).pdf]
0 ÒýÑÔ
ñ£ºÛ¸í´ñÇгýºóÒ׸´·¢£¬ÖÎÁƽÏΪ¼¬ÊÖ£¬ÊÇĿǰÕûÐÎÍâ¿ÆµÄÄÑÌâÖ®Ò»[1-2]¡£ÊÖÊõÇгýºÍÒ©Îï×¢ÉäÖÎÁÆÈÔÊdz£ÓõÄÖ÷ÒªÖÎÁÆ·½·¨¡£ÓÃÓÚ·ÀÖÎñ£ºÛ¸í´ñµÄÒ©ÎïÖÖÀà½Ï¶à£¬½üÄêÀ´£¬¹úÄÚÍⱨµÀÓ¦Óô«Í³¿¹´úлҩÎï5-·úÄòà×षÀÖ¹ÏËά»¯£¬ÔÚÖÎÁÆñ£ºÛ¸í´ñ·½ÃæÈ¡µÃÁËÒ»¶¨µÄÁÙ´²ÁÆÐ§[3-7]£¬µ«¶ÔÆä×÷ÓûúÖÆÒÔ¼°ÁÙ´²Ò©ÎïÓ¦ÓõÄŨ¶ÈÉÐÎÞÈ·ÇÐÈ϶¨¡£±¾ÊµÑé²ÉÓÃËļ׻ùżµªßòÑη¨¡¢Á÷ʽϸ°ûÊõ·ÖÎö·¨¡¢Hoechst 33258Ó«¹âȾɫ·¨£¬¹Û²ìÁË5-·úÄòà×शÔÌåÍâÅàÑøñ£ºÛ¸í´ñ³ÉÏËάϸ°ûÔöÖ³ºÍµòÍöµÄÉúÎïѧӰÏ죬ּÔÚΪҩÎïÁÙ´²Ó¦ÓÃÌṩʵÑéÒÀ¾Ý¡£
1 ²ÄÁϺͷ½·¨
Éè¼Æ£ºÖظ´²âÁ¿¹Û²ì¡£
µ¥Î»£º°²»ÕÒ½¿Æ´óѧµÚÒ»¸½ÊôÒ½ÔºÕûÐÎÍâ¿Æ¡£
¶ÔÏó£ºÊµÑéÓÚ2006-08/2007-07ÔÚ°²»ÕÒ½¿Æ´óѧ΢ÉúÎï½ÌÑÐÊÒ¼°°²»ÕÒ½¿Æ´óѧ¸½ÊôÒ½ÔºÖÐÐÄʵÑéÊÒÍê³É¡£6Àýñ£ºÛ¸í´ñ£¨¶ú´¹¡¢´óÍȸ÷1Àý¡¢ÐØÇ°¡¢Éϱ۸÷2Àý£©¾ùΪ°²»ÕÒ½¿Æ´óѧ¸½ÊôÒ½ÔºÕûÐÎÍâ¿ÆÊÖÊõ²¡Àý£¬ÄêÁä19~28Ë꣬ÄÐ2Àý£¬Å®4Àý£¬²¡³Ì1~3Ä꣬¾ùÎÞϵͳÐÔ¼²²¡ºÍ¼¤ËØ¡¢ÆäËûÒ©Îï×¢ÉäÊ·£¬¶ÔÓÃÓÚʵÑéµÄËùÈ¡×éÖ¯»¼Õß¾ùÖªÇéͬÒâ¡£ÖÎÁÆ·½°¸¾Ò½ÔºÒ½Ñ§Â×ÀíίԱ»áÅú×¼¡£
Ö÷ÒªÊÔ¼Á¼°ÒÇÆ÷£ºDMEM¡¢Hoechst 33258Ó«¹âȾɫ¼Á(Gibco¹«Ë¾)£»Ð¡Å£ÑªÇå(º¼ÖÝËļ¾ÇàÉúÎ﹤³Ì²ÄÁÏÓÐÏÞ¹«Ë¾)£»5-·úÄòà×à¤(Ìì½ò¹âÒ«°±»ùËáÓÐÏÞ¹«Ë¾£¬¹æ¸ñ£ºÃ¿Ö§250 mg/10 mL)£»Ëļ׻ùżµªßòÑΡ¢PI(Sigma¹«Ë¾)¡£Á÷ʽϸ°ûÒÇ£¨FACScanÐÍ£¬ÃÀ¹úBD¹«Ë¾£©¡£
Éè¼Æ¡¢ÊµÊ©¡¢ÆÀ¹ÀÕߣºÊµÑéÉè¼ÆÎªµÚÒ»¡¢¶þ×÷Õߣ¬¸ÉԤʵʩΪµÚÒ»¡¢ËÄ×÷Õߣ¬ÆÀ¹ÀΪµÚ¶þ¡¢Èý×÷Õߣ¬¾ùÊܹýÏà¹ØÊµÑéµÄÕý¹æÅàѵ¡£
·½·¨£º
ñ£ºÛ¸í´ñ³ÉÏËάϸ°ûÅàÑø£º½«×éÖ¯±ê±¾Óú¬100 U/L ÇàÃ¹ËØºÍ100 U /L Á´Ã¹ËصÄÁ×ËáÑλº³åÒº·´¸´³åÏ´3´Î£¬È¥Æ¤ÏÂ×éÖ¯ºÍ±íƤ£¬¼ô³É1 mm¡Á1 mm¡Á1 mm ×óÓÒµÄС¿é£¬¾ùÔÈ·Ö²¼ÓÚÅàÑøÆ¿µ×£¬¼ÓÈëÉÙÁ¿º¬Ìå»ý·ÖÊýΪ0.15СţѪÇåµÄDMEMÒº£¬ÖÃÈëÎÂÏäÔ´úÅàÑø¡£´ýϸ°ûÈںϺ󴫴ú£¬ÊµÑéËùÓÃϸ°û¾ùΪµÚ4~8´ú´¦ÓÚ¶ÔÊýÉú³¤ÆÚµÄ³ÉÏËάϸ°û¡£
Ëļ׻ùżµªßòÑ稣º½«¶ÔÊýÉú³¤ÆÚµÄ³ÉÏËάϸ°ûÃܶÈÉ趨Ϊ2.5¡Á105/¿×£¬½ÓÖÖÓÚ96¿×°åÖУ¬ 200 ¦ÌL/¿×£¬ÅàÑø24 h£¬´ýϸ°ûÌù±Úºó»»Òº£¬²¢¼ÓÈ뺬ÖÕŨ¶È·Ö±ðΪ0.1£¬0.2£¬0.4£¬0.8£¬1.6 g/L 5-·úÄòà×वÄÅàÑøÒº£¬Éè¶ÔÕÕ¿×£¨²»º¬5-·úÄòà×ण©ºÍ¿Õ°×¿×£¨½öº¬Ëļ׻ùżµªßòÑΣ©£¬Ã¿¿×Ìå»ý¾ùΪ100 ¦ÌL£¬ÅàÑø72 h ºó£¬¼ÓÈë5 g/L Ëļ׻ùżµªßòÑÎ30 ¦ÌL£¬¼ÌÐøÅàÑø4 h£¬ÆúÉÏÇåºó¼ÓÈë¶þ¼×ÑÇ·Ó100 ¦ÌL£¬Î¢Á¿Õñµ´Æ÷Õñµ´10 min£¬Ã¸ÁªÃâÒß·Ö¹âÒÇ490 nm ¼ÆÊýÎü¹â¶È£¨A£©Öµ£¬ÒÖÖÆÂÊ(%)=1- [£¨AʵÑé¿×-A¿Õ°×¿×£©/£¨A¶ÔÕÕ¿×-A¿Õ°×¿×£©]¡Á100%£¬Í¨¹ý×÷ͼ·¨£¬Çó³ö5-·úÄòà×शԳÉÏËάϸ°û°ëÊýÒÖ֯ō¶È£¨IC50Öµ£©¡£
Á÷ʽϸ°ûÊõ·ÖÎö·¨£º½«³ÉÏËάϸ°û½ÓÖÖÓÚ6¿×°åÖУ¬ÊýÄ¿´ïµ½1¡Á106/¿×ÒÔÉÏ£¬²¢¼ÓÈ뺬ÖÕŨ¶È·Ö±ðΪ0.2£¬0.3£¬0.4£¬0.5£¬0.6 g/L 5-·úÄòà×वÄÅàÑøÒº£¬Éè¶ÔÕտס£ÅàÑø 48 h ºó£¬ÆúÉÏÇ壬ÒÈøÏû»¯£¬Á×ËáÑλº³åÒºÇåÏ´2±é¡£Ìå»ý·ÖÊýΪ0.75µÄÒÒ´¼l mL Ðü¸¡Ï¸°û£¬¹Ì¶¨£¬ÀëÐÄÈ¥ÉÏÇå¡£Á×ËáÑλº³åÒºÇåÏ´2±éºóÐü¸¡Ï¸°û£¬¼ÓÈËRnaseÖÁÖÕŨ¶È25 mg/L£¬37 ¡æ£¬×÷ÓÃ1 h£¬ÐÐϸ°ûPIȾɫ(PIÒºÖÕŨ¶È50~100 mg/L)£¬4¡æ ±Ü¹âȾɫ£¬45 min ºóÉÏ»ú¡£²âÁ¿Ï¸°ûµòÍöÂʺÍϸ°ûÖÜÆÚ°Ù·ÖÊý¡£
³ÉÏËάϸ°ûµòÍöµÄÐÎ̬¹Û²ì£º½«³ÉÏËάϸ°û½ÓÖÖÓÚÔ¤ÏÈÆÌºÃ²£Æ¬µÄ6¿×ϸ°ûÅàÑø°åÖУ¬µ÷Õûϸ°ûÃܶÈʹϸ°ûÈں϶ÈÔ¼50%~80%ΪÒË¡£
ÅàÑø24 hºó£¬¼ÓÈ뺬ÖÕŨ¶È·Ö±ðΪ0.2£¬0.3£¬0.4£¬ 0.5£¬0.6 g/L 5-·úÄòà×वÄÅàÑøÒº£¬Éè¶ÔÕÕ¿×£¬ÅàÑø48 h ºó£¬Îü³ýÅàÑøÒº£¬¼ÓÈë2 mL ÐÂÏÊÅäÖÆ1¡Ã3µÄ±ù´×Ëá/¼×´¼¹Ì¶¨Òº£¬¾²Öà 15 min ºó£¬Îü³ý¹Ì¶¨Òº¡£ÓÚ¸÷¿×ÖмÓÈë0.2% Hoechst 33258ȾҺ2 mL£¬±Ü¹â30 min Ⱦɫ£¬ÎüµôȾҺ£¬ÕôÁóˮϴµÓ3´Î£¬Îü¸É£¬·×ªµ¹ÖÃÔÚÔØ²£Æ¬ÉÏ£¬µÎ¼ÓÄûÃÊËỺ³åÒº£¨pH 5.5£©ÊýµÎ·â¹Ì£¬Ó«¹âÏÔ΢¾µ¹Û²ìµòÍöϸ°ûÐÎ̬¡£
Ö÷Òª¹Û²ìÖ¸±ê£º¢Ù¸÷Ũ¶È5-·úÄòà×शÔñ£ºÛ¸í´ñ³ÉÏËάϸ°ûµÄÒÖÖÆÂʼ°°ëÊýÒÖ֯ō¶È£¨IC50£©¡£¢Úϸ°ûµòÍöÂʺÍϸ°ûÖÜÆÚ°Ù·ÖÊý¡£¢Ûϸ°ûµòÍöµÄÐÎ̬¡£
ͳ¼ÆÑ§·½·¨£ºÓɵÚÒ»×÷Õß²ÉÓÃSPSS 10.0Èí¼þÍê³Éͳ¼Æ´¦Àí£¬ÊµÑéÊý¾ÝÒÔ_x¡Às±íʾ£¬Êý¾Ý¾×ª»»ºó²ÉÓÃÅä¶Ôt¼ìÑé±È½Ï´¦Àí×éÓë¶ÔÕÕ×éÒÔ¼°¸÷´¦Àí×é¼ä²î±ð£¬P < 0.05Ϊ²îÒìÓÐÏÔÖøÐÔÒâÒå¡£
2 ½á¹û
2.1 ñ£ºÛ¸í´ñ³ÉÏËάϸ°ûÅàÑø 6ÀýÊÖÊõÇÐÈ¡µÄñ£ºÛ¸í´ñ±ê±¾×éÖ¯£¬Ô´úÅàÑø³ÉÏËάϸ°ûÈ«²¿³É»î£¬ÐÎ̬Õý³£¡£
2.2 Ëļ׻ùżµªßòÑη¨¼ì²â½á¹û ¼û±í1¡£
¾Å¨¶È·Ö±ðΪ0.1£¬0.2£¬0.4£¬0.8£¬1.6 g/L 5-·úÄòà×सÉÔ¤72 h ºó£¬¸÷×é¼äÁ½Á½±È½Ï²îÒì¾ùÓÐÏÔÖøÐÔ£¨P < 0.01£©¡£Í¨¹ý×÷ͼÇóµÃ°ëÊýÒÖ֯ō¶ÈIC50Ϊ£¨0.400¡À0.032£©g/L£¬±¾ÊµÑéÔÙÑ¡ÓýӽüIC50µÄ5¸öŨ¶È£º0.2£¬0.3£¬0.4£¬0.5£¬0.6 g/L£¬×÷ΪÓàÏÂʵÑéŨ¶È¡£
2.3 Á÷ʽϸ°ûÒǼì²â½á¹û ÒÔ²»Í¬Å¨¶È0.2£¬0.3£¬0.4£¬0.5£¬0.6 g/L Ò©Îï´¦Àí48 h ºó£¬¾Á÷ʽϸ°ûÒǶ¨Á¿ÏÔʾ£¬Ï¸°ûµòÍöÂÊ·Ö±ðΪ£¨4.160¡À0.370£©%¡¢(6.340¡À0.410)%¡¢(10.020¡À0.720)%¡¢(12.230¡À0.640)%¡¢(14.340¡À0.860)%£¬×é¼äÁ½Á½±È½Ï²îÒìÓÐÏÔÖøÐÔÒâÒ壨P < 0.05£©£»Óë¶ÔÕÕ×飨0.400¡À0.013£©%±È½Ï£¬²îÒì¾ùÓÐÏÔÖøÐÔ(P < 0.01)¡£Óë¶ÔÕÕ×éϸ°ûÖÜÆÚ°Ù·ÖÊý±È½Ï£¬±íÏÖΪG0/G1ÆÚÍ£ÖÍ£¬SÆÚ¼õÉÙ¡£¼û±í2¡£
2.4 Hoechst 33258Ó«¹âȾɫ¹Û²ìϸ°ûµòÍöÐÎ̬ ϸ°ûµòÍö¹ý³ÌÖУ¬ÔçÆÚϸ°ûºË³Ê²¨ÎÆ×´»òÕÛ·ìÑù£¬²¿·ÖȾɫÖʳöÏÖŨËõ״̬£»ÖÐÍíÆÚµòÍöϸ°ûµÄºËȾɫÖʸ߶ÈÄý¼¯£¬±ßÔµ»¯£¬Ï¸°ûºËÁѽâΪËé¿é£¬²úÉúµòÍöСÌ壬¼ûͼ1£»¶ÔÕÕ×éϸ°ûÄÚδ¼ûºËŨËõ£¬¼ûͼ2¡£

3 ÌÖÂÛ
5-·úëåà×à¤×÷Ϊ´«Í³¿¹´úлҩÎ¿ÉÒÖÖÆDNAºÏ³É£¬ÆäÓÕµ¼¶àÖÖÖ×Áöϸ°ûµòÍöµÄ×÷ÓÃÒѵõ½³ä·ÖÂÛÖ¤[8-9]¡£µ«5-·úÄòà×षÀÖ¹ÏËά»¯µÄ»úÖÆÉв»Ã÷È·¡£
ϸ°ûµòÍöÊÇKerrµÈ[10]ÓÚ1972ÄêÌá³öµÄ£¬ÔÚά³Ö»úÌåÄÚÔÚÆ½ºâ·½ÃæÆð·Ç³£ÖØÒªµÄ×÷Óá£ÈËÃÇÍÆÂÛÔÚñ£ºÛµÄ·¢ÉúÓë´´ÉËÐÞ¸´¹ý³ÌÖУ¬³ÉÏËάϸ°ûÕý³£³ÌÐòÐÔϸ°ûËÀÍö
»úÖÆµÄÕϰÊdzÉÏËάϸ°ûÔöÖ³£¬·ÖÃÚ¹ý¶àµÄ½ºÔºÍϸ°ûÍâ»ùÖÊ£¬µ¼Ö²¡ÀíÐÔñ£ºÛ·¢ÉúµÄÖØÒª»úÖÆ¡£
±ÊÕßÔÚʵÑéÖУ¬Í¨¹ýËļ׻ùżµªßòÑαÈÉ«·¨·¢ÏÖ£¬5-·úÄòà×à¤ÔÚÌåÍâ¶Ôñ£ºÛ¸í´ñ³ÉÏËάϸ°ûÓÐÃ÷ÏÔÒÖÖÆ×÷Óã¨P < 0.01£©£¬ÇÒ¾ßÓÐŨ¶ÈÒÀÀµÐÔ¡£Îª×¼È·¹Û²ìϸ°ûµÄµòÍöºÍϸ°ûÖÜÆÚ±ä»¯£¬Ó¦Ñ¡ÔñÄÜÃ÷ÏÔÒÖÖÆÔöÖ³£¬Í¬Ê±¶Ôϸ°û¶¾ÐÔ½ÏСµÄŨ¶ÈÈ¥¸ÉÔ¤ñ£ºÛ¸í´ñ³ÉÏËάϸ°û¡£¼´ÒÔ½Ó½üIC50Öµ[£¨0.400¡À0.032£©g/L]µÄŨ¶È£¬Éè¼Æ²»Í¬Å¨¶È£¨0.2£¬0.3£¬0.4£¬0.5£¬0.6 g/L£©¡£ÎªÁ˱ÜÃâ5-·úÄòà×ळ¤Ê±¼ä×÷ÓÃϸ°ûºó£¬»µËÀϸ°ûÔö¶à£¬¶øÓ°Ïìϸ°ûµòÍöÂʵÄ׼ȷ²â¶¨£¬±ÊÕßÑ¡ÓÃÁ˸ÉÔ¤48 h£¬Á÷ʽϸ°ûÊõ¶¨Á¿ÏÔʾ£¬ËæÒ©ÎïŨ¶ÈµÄÔö¼Ó£¬Ï¸°ûµòÍöÂÊËæÖ®Éý¸ß¡£
µòÍöºÍ»µËÀÊÇϸ°ûËÀÍöµÄÁ½ÖÖ·½Ê½¡£µòÍöÊÇÊÜ»ùÒòµ÷¿Ø¡¢Ï¸°ûÖ÷¶¯²ÎÓëÇÒ×ÔÉíÓÐÒ»¶¨³ÌÐòµÄÉúÀíÐÔËÀÍö¹ý³Ì£¬ÓֳƳÌÐòÐÔϸ°ûËÀÍö»òϸ°û×Ôɱ¡£»µËÀÊÇÍâ½çËðÉËÒòËØÖ±½ÓÆÆ»µÏ¸°ûµÄÉúÎïĤºÍÄÜÁ¿´úл£¬µ¼ÖÂϸ°ûÉúÃüµÄ±»¶¯Öжϡ£ÐÎ̬ѧµÄ¸Ä±äÊÇÅжϵòÍö»ò»µËÀµÄÖ÷ÒªÒÀ¾Ý[11]¡£±¾ÊµÑéHoechst 33258Ó«¹âȾɫ½á¹ûÏÔʾ£¬²»Í¬Å¨¶È5-·úÄòà×सÉÔ¤48 h ºó£¬Ó«¹âÏÔ΢¾µÏ¹۲ì³ÉÏËάϸ°û¾ù·¢Éú²»Í¬³Ì¶ÈµòÍö£¬½ö¼ûºÜÉÙÁ¿»µËÀϸ°û¡£ËµÃ÷ÔÚʵÑéÒ©ÎïŨ¶ÈÏ£¬Ï¸°û±íÏÖΪµòÍö¶ø·Ç»µËÀ¡£Í¨¹ýËļ׻ùżµªßòÑαÈÉ«·¨²âµÃµÄϸ°ûÒÖÖÆÂʺÍÁ÷ʽϸ°ûÊõ¼ì²âµÄµòÍöÂÊÓÐËù²îÒ죬Õâ¿ÉÄÜÊÇÒòΪËļ׻ùżµªßòÑαÈÉ«·¨¼ì²âµÄϸ°ûÒÖÖÆÂʰüÀ¨Ï¸°ûËÀÍöºÍϸ°ûÔöÖ³ÒÖÖÆÁ½¸ö·½Ã棬¶øÏ¸°ûµÄËÀÍöÓÖ°üÀ¨Ðí¶àµòÍöϸ°ûºÍ¼«ÉÙÊý»µËÀϸ°û¡£Òò´Ë£¬Ñ¡ÓÃÒ»¸ö×î¼ÑŨ¶È£¬¼ÈÄÜÒÖÖÆÏ¸°ûÔöÖ³£¬Í¬Ê±ÓÖ¶Ôϸ°û¶¾ÐÔ½ÏСµÄŨ¶È£¬È¥¹Û²ìϸ°ûµÄµòÍöºÍϸ°ûÖÜÆÚ±ä»¯ÉõÎªÖØÒª[12]¡£
Ñо¿ÈÏΪ£¬ñ£ºÛ¸í´ñµÄÐγÉÓëBcl-2ÒÖµòÍö»ùÒò¸ß±í´ïÃÜÇÐÏà¹Ø[13]¡£½µµÍñ£ºÛ¸í´ñÖÐÒÖµòÍö»ùÒòµÄ¸ß±í´ï£¬¿ÉÄÜÊÇÖÎÁÆñ£ºÛ¸í´ñµÄÒ»ÖÖеÄÓÐЧ·½·¨[14]¡£5-·úÄòà×शԳÉÏËάϸ°ûÓÐÓÕµ¼µòÍöµÄ×÷Óã¬Æä¶ÔÏà¹ØµòÍö»ùÒò×÷ÓÃͨ·ÓдýÓÚ½øÒ»²½Ñо¿[15]¡£
±¾ÊµÑéÖÐ5-·úÄòà×सÉÔ¤³ÉÏËάϸ°û×÷ÓÃ48 h ºó£¬Óë¶ÔÕÕ×é±È½Ï£¬ÊµÑé×éϸ°ûÖÜÆÚ°Ù·ÖÊý±íÏÖΪG0/G1ÆÚÍ£ÖÍ£¬SÆÚ¼õÉÙ£¨P < 0.05£©¡£Ï¸°ûÖÜÆÚµÄµ÷½ÚÖ÷ÒªÊÇͨ¹ýһϵÁÐϸ°ûÖÜÆÚÒò×ӵĵ÷¿Ø¶øÊµÏÖ¡£Ñо¿±íÃ÷£¬Ï¸°ûÖÜÆÚËØD1ºÍCDK4Òò×Ó×÷Ϊϸ°û·ÖÁÑÖÜÆÚÆðʼµãG0/G1ÆÚµÄÕýÐÔµ÷½ÚÒò×Ó£¬¿Éʹϸ°û·ÖÁѼÓËÙ¡£5-·úÄòà×शԳÉÏËάϸ°ûµÄÒÖÖÆ×÷ÓÿÉÄÜÖ±½Ó»ò¼ä½ÓµØÓëϸ°ûÖÜÆÚËØD1ºÍCDK4»ùÒòµÄ±í´ïÓйØ[16]¡£
×ܽá½üÄêÀ´¶àÊýѧÕßµÄÑо¿·¢ÏÖ[17-19]£¬5-·úÄòà×à¤ÖÎÁÆñ£ºÛµÄÖ÷Òª×÷ÓûúÖÆ¿ÉÄÜÓУº¢ÙÒÖÖÆ³ÉÏËάϸ°ûÔöÖ³¡£¢Ú½µµÍ³ÉÏËάϸ°û½ºÔºÏ³ÉºÍ·ÖÃÚÄÜÁ¦¡£¢ÛÓÕµ¼³ÉÏËάϸ°ûµòÍö¡£¢ÜÒÖÖÆñ£ºÛÄÚ¾Ö²¿Ñª¹ÜÔöÉú¡£µ«Ä¿Ç°ÁÙ´²ÉÏÓ¦ÓÃ5-·úÄòà×वķ½·¨ºÍ×î¼ÑŨ¶ÈÈÔ²»È·ÇС£Fitzpatrick[20]Ôø¶Ô100¶àÀýñ£ºÛ¸í´ñ»¼Õß²¡ËðÄÚ×¢Éä¸ßŨ¶È5-·úÄòà×ण¨25 g/L£©£¬×¢Éä¼ä¸ôÆÚ´ÓÿÖܶþÈý´Îµ½Ã¿¶þÈýÖÜ1´Î£¬ÖÎÁÆÐ§¹û½ÏºÃ¡£·úÄòà×िÉÒýÆð¾Ö²¿Æ¤·ôºì°ß¡¢Ë®Öס¢ÆÆÀ£¡¢É«ËسÁ×Å¡£±¾ÊµÑéÓ¦ÓýϵÍŨ¶È5-·úÄòà×सÉÔ¤ÌåÍâÅàÑøñ£ºÛ¸í´ñ³ÉÏËάϸ°û£¬¿ÉÒÖÖÆÏ¸°ûÔöÖ³ºÍÓÕµ¼Ï¸°ûµòÍö¡£²¢·¢ÏÖµÍŨ¶ÈÒ©ÎïÒýÆðϸ°û»µËÀµÄ±ÈÂʽϵͣ¬ÏàÓ¦ÁÙ´²ÉϾֲ¿¸±×÷ÓýÏÉÙ£¬ÇÒ5-·úëåà×़۸ñµÍÁ®£¬²ÉÓõÍŨ¶È¡¢¶ÌÖÜÆÚ×¢Éä5-·úÄòà×िÉÄÜÊÇÖÎÁÆñ£ºÛ¸í´ñµÄÒ»ÖÖа²È«ÓÐЧ·½·¨¡£Æä×÷ÓûúÖÆºÍÁÙ´²Ó¦Ó÷½·¨ÈÔÓдýÓÚ½øÒ»²½Ñо¿¡£
4 ²Î¿¼ÎÄÏ×
1 Al-Attar A£¬Mess S£¬Thomassen JM£¬et al. Keloid pathogenesis and treatment. Plast Reconstr Surg 2006;117(1):286-300
2 Urioste SS£¬Arndt KA£¬Dover JS. Keloids and hypertrophic scars£ºreview and treatment strategies. Semin Cutan Med Surg 1999£»18(2):159-171
3 Sun Y£¬Wang LX£¬Wang L£¬et al. A comparison of the effectiveness of mitomycin C and 5-fluorouracil in the prevention of peridural adhesion after laminectomy. J Neurosurg Spine 2007£»7(4)£º423-428
4 Yildiz KH£¬Gezen F£¬Is M£¬et al. Mitomycin C£¬5-fluorouracil£¬and cyclosporin A prevent epidural fibrosis in an experimental laminectomy model. Eur Spine J 2007;16(9):1525-1530
5 Wojtulewicz M£¬Rekas M£¬Wierzbowska J. Subconjuctival application of 5-fluorouracil (5-FU) following surgical treatment of glaucoma with deep sclerectomy-indications£¬complications and initial evaluation of effectiveness. Klin Oczna 2005;107(4-6):232-235
6 Viveiros MM£¬Schellini SA£¬Candeias J£¬et al. Exposure of normal Tenon's capsule fibroblasts from pterygium to 5-fluorouracil and mitomycin C. Arq Bras Oftalmol 2007;70(1):73-77
7 Roseborough IE£¬Grevious MA£¬Lee RC. Prevention and treatment of excessive dermal scarring. J Natl Med Assoc 2004;96(1):108-116
8 Matsuhashi N£¬Saio M£¬Matsuo A£¬et al. Apoptosis induced by 5-fluorouracil, cisplatin and paclitaxel are associated with p53 gene status in gastric cancer cell lines. Int J Oncol 2005;26(6):1563-1567
9 Ocker M£¬Alajati A£¬Ganslmayer M£¬et al. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 2005;131(6):385-394
10 Kerr JF£¬Wyllie AH£¬Currie AR. Apoptosis£ºa basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972£»26(4)£º239-257
11 ³É¾ü.³ÌÐòÐÔϸ°ûËÀÍöÓë¼²²¡[M].±±¾©£º±±¾©Ò½¿Æ´óѧÖйúкÍÒ½¿Æ´óѧÁªºÏ³ö°æÉç,1996:1-2
12 Wendling J£¬Marchand A£¬Mauviel A£¬et al. 5-fluorouracil blocks transforming growth factor-beta-induced alpha 2 type I collagen gene (COL1A2) expression in human fibroblasts via c-Jun NH2-terminal kinase/activator protein-1 activation. Mol Pharmacol 2003;64(3):707-713
13 Sayah DN, Soo C, Shaw WW, et al. Downregulation of apoptosis-related genes in keloid tissues. J Surg Res 1999; 87(2):209-216
14 Ladin DA£¬Hou Z£¬Patel D£¬et al. P p53 and apoptosis alterations in keloids and keloid fibroblasts. Wound Repair Regen 1998£»6(1)£º28-37
15 Liu Y,Ren LS,Cen Y. Zhongguo Xiufu Chongjian Waike Zazhi 2001;15(6):351-353
ÁõÓ£¬ÈÎÁÖÉ£¬á¯çø.Bcl-2ºÍFas»ùÒòÔÚñ£ºÛ³ÉÏËάϸ°ûÖеıí´ï[J].ÖйúÐÞ¸´Öؽ¨Íâ¿ÆÔÓÖ¾,2001,15(6):351-353
16 Kojiro S£¬Yano H£¬Ogasawara S£¬et al. Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. J Gastroenterol Hepatol 2006;21(1 Pt 1):129-137
17 Bulstrode NW£¬Mudera V£¬McGrouther DA£¬et al. 5-fluorouracil selectively inhibits collagen synthesis. Plast Reconstr Surg 2005;116(1):209-221;discussion 222-223
18 Gong YY£¬Li XJ£¬Wang ML£¬et al. Zhongguo Zuzhi Gongcheng Yanjiu Yu Linchuang Kangfu 2007;11(6):1060-1063
¹¨éóÒ»£¬ÀîС¾²£¬ÍõÃ÷Àö£¬µÈ.³ÉÏËάϸ°û·ÖÃÚ½ºÔµ°°×Óë5-·úÄòà×वÄʱ¼äÒÖÖÆÐ§Ó¦[J].Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´,2007,11(6):1060-1063
19 Wu XL£¬Liu W£¬Cao YL. Zhonghua Zhengxing Waike Zazhi 2006;22(1):44-46
ÎäÏþÀò£¬Áõ࣬²ÜÒêÁÖ.µÍŨ¶È5-·úÄòà×à¤ÒÖÖÆÑª¹ÜÔöÉúÔÚñ£ºÛ¸í´ñ×ÛºÏÖÎÁÆÖеÄ×÷Óóõ̽[J].ÖлªÕûÐÎÍâ¿ÆÔÓÖ¾,2006,22(1):44-46
20 Fitzpatrick RE. Treatment of inflamed hypertrophic scars using intralesional 5-FU. Dermatol Surg 1999;25(3):224-232
|